ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Japan's Takeda in push to debut COVID-19 treatment this year

Drugmaker joins big pharma's commitment to pool resources in fight against virus

Takeda hopes to launch an antibody treatment for COVID-19 this year.   © Reuters

NEW YORK -- Japanese drugmaker Takeda Pharmaceutical is aiming to roll out an antibody treatment for COVID-19 as early as this year, as it joins global big pharma's pledge to rise to the occasion amid a global pandemic.

"We believe that within nine to 18 months we could have a product that has real potential to treat the most critically ill patients," Rajeev Venkayya, president of Takeda's global vaccine business unit, said Thursday.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more